United States Patent 9,067,896: Scope, Claim Boundaries, and Landscape
US Drug Patent 9,067,896 is claim-led and crystallinity-defined. The enforceable scope centers on specific salt identities (monophosphoric acid salt and hydrochloride salt) paired with specific solid forms for those salts (Form A and Form B for the monophosphoric acid salt; crystallinity for the hydrochloride salt), each anchored to X-ray powder diffraction (XRPD) peak sets and, for the monophosphoric acid Form A, DSC onset/thermogram features. The claim set is structured to capture both (1) the salt as a chemical entity and (2) the salt as a reproducible solid state product defined by analytical fingerprints.
What is the core claimed subject matter?
The claims recite two salt branches, each with sub-branches defined by form and solid-state characterization.
Monophosphoric acid salt branch
- Claim 1: “A monophosphoric acid salt of the compound of Formula I.”
- Claim 2: “The monophosphoric acid salt of claim 1 which is the anhydrous crystalline monophosphoric acid salt.”
- Claims 3–9: Anhydrous crystalline monophosphoric acid salt Form A, defined by:
- XRPD characteristic peak at ~15° (2θ) (Claim 3)
- Additional peak sets:
- 13.7°, 16.8°, 21.3°, 22.4° (Claim 4)
- 9.2°, 9.6°, 18.7°, 20.0°, 22.9°, 27.2° (Claim 5)
- “At least 3 characteristic peaks” selected from 13.7°, 15°, 16.8°, 21.3°, 22.4° (Claim 6)
- “Substantially as shown in FIG. 1B” (Claim 7)
- DSC onset of an endotherm at about 184°C (Claim 8)
- “Substantially as shown in FIG. 2B” (Claim 9)
- Claims 10–11: Anhydrous crystalline monophosphoric acid salt Form B, defined by:
- XRPD characteristic peaks selected from 9.3°, 12.5°, 13.4°, 15.8°, 17° (Claim 10)
- “Substantially as shown in FIG. 1C” (Claim 11)
Hydrochloride salt branch
- Claim 12: “The hydrochloride salt of the compound of Formula I.”
- Claim 13: “The hydrochloride salt of claim 12 which is a crystalline dihydrate.”
- Claim 14: Crystalline hydrochloride salt XRPD peak set selected from 10.9°, 12.1°, 14.8°, 20.5°, 22°, 25.1° (Claim 14).
- Claim 15: “Substantially as shown in FIG. 1E” (Claim 15)
How are the claims drafted to narrow enforceability?
This is a classic “solid form by analytical parameters” drafting strategy. Each branch funnels infringement toward products that match both:
1) the salt type and hydration state (anhydrous vs dihydrate), and
2) the analytical signature (XRPD peak presence plus DSC thermal profile in Form A).
Salt identity and state gates
- Form A and Form B are only relevant inside the anhydrous crystalline monophosphoric acid salt envelope (Claims 2–6 and 10–11).
- Crystalline hydrochloride is further gated by dihydrate (Claim 13). That limits coverage against anhydrous HCl salt and amorphous HCl salt (depending on how “crystalline” is proven).
XRPD is the dominant infringement trigger
Most dependent claims are built on “comprises one or more characteristic peaks… selected from peaks at about…” or “comprising… at least 3 characteristic peaks… selected from…” plus “substantially as shown in FIG.” This creates a claim structure that is both:
- flexible (peak “selected from” sets; “one or more”; “at least 3”), and
- falsifiable (XRPD peak positions at specific 2θ values).
DSC only appears for Form A
- Claims 8 and 9 add a thermal signature gate for Form A: DSC onset of an endotherm at about 184°C and a “substantially as shown in FIG. 2B” reference.
From a scope perspective, this means:
- A competitor who matches XRPD for Form A but has materially shifted DSC events could still avoid Claims 8–9 while potentially landing on Claims 3–7 and/or 6, depending on the XRPD match.
- A competitor who shifts XRPD enough to avoid the Form A peak set can avoid most of Claims 3–7 and 6 at the same time.
What is the practical scope of each claim (element-by-element)?
The following table converts the claims into enforceability elements.
| Claim |
Claimed product |
Key required features |
Main infringement test |
| 1 |
Monophosphoric acid salt of Formula I compound |
Salt identity only |
Presence of monophosphoric acid counterion |
| 2 |
Monophosphoric acid salt |
Anhydrous crystalline |
Crystalline + anhydrous state proof |
| 3 |
Form A |
XRPD includes peak ~15° (2θ) |
XRPD peak at ~15° |
| 4 |
Form A |
Adds peaks from 13.7°, 16.8°, 21.3°, 22.4° |
XRPD contains the selected peaks (claim allows “one or more”) |
| 5 |
Form A |
Adds peaks from 9.2°, 9.6°, 18.7°, 20.0°, 22.9°, 27.2° |
XRPD contains selected peaks |
| 6 |
Form A (broader peak-set logic) |
XRPD has at least 3 peaks selected from 13.7°, 15°, 16.8°, 21.3°, 22.4° |
XRPD contains ≥3 of the enumerated peaks |
| 7 |
Form A |
“Substantially as shown in FIG. 1B” |
XRPD similarity to reference pattern |
| 8 |
Form A |
DSC endotherm onset ~184°C |
DSC event timing |
| 9 |
Form A |
“Substantially as shown in FIG. 2B” |
DSC thermogram similarity |
| 10 |
Form B |
XRPD has peaks selected from 9.3°, 12.5°, 13.4°, 15.8°, 17° |
XRPD contains selected peaks |
| 11 |
Form B |
“Substantially as shown in FIG. 1C” |
XRPD similarity to reference |
| 12 |
Hydrochloride salt |
Salt identity only |
HCl counterion presence |
| 13 |
Hydrochloride |
Crystalline dihydrate |
Crystalline + dihydrate water content |
| 14 |
Crystalline HCl dihydrate |
XRPD has peaks from 10.9°, 12.1°, 14.8°, 20.5°, 22°, 25.1° |
XRPD contains selected peaks (“one or more”) |
| 15 |
Crystalline HCl dihydrate |
“Substantially as shown in FIG. 1E” |
XRPD similarity |
How much design-around space exists within the claim logic?
1) XRPD “selected from” creates both flexibility and risk
Because several dependent claims use “one or more” and others use “at least 3,” infringement can still occur even if a product does not match the entire peak list, as long as it satisfies the selection threshold.
- Form A Claim 6 is the biggest design constraint: it requires at least 3 peaks selected from five candidate peaks (13.7°, 15°, 16.8°, 21.3°, 22.4°). A design-around would need to ensure the product does not retain at least three of those peaks at the claimed positions “about” those values.
- Form B Claim 10 uses “one or more” from a five-peak set. That is a lower bar: retaining even a single enumerated peak can satisfy the dependent claim, assuming the other claim prerequisites are met (anhydrous crystalline monophosphoric acid salt + Form B labeling logic).
2) “Substantially as shown in FIG.” tightens the net
Claims 7, 9, 11, and 15 incorporate figure-based pattern/thermogram comparisons. In practice, these can reduce the value of “near miss” strategies if the examiner or court interprets “substantially” broadly.
3) DSC gate is narrower than XRPD
Claims 8–9 apply only to Form A and only if the DSC feature is present. That is not a universal avoidance method, because Claims 3–7 and 6 already cover Form A on XRPD grounds.
4) Hydration state is a hard boundary for hydrochloride
Claim 13 limits the hydrochloride to a crystalline dihydrate. A shift to anhydrous crystalline HCl or a different hydrate level can potentially exit the dihydrate requirement, though “crystalline hydrochloride salt” in Claim 12 remains broad.
What is the patent landscape implication of this claim architecture?
This patent looks like a polymorph/salt-form protection layer rather than a broad composition-of-matter claim. The enforceable value sits in manufacturing-controlled product attributes:
- which salt is used (monophosphoric acid vs hydrochloride),
- whether the product is anhydrous vs dihydrate,
- which solid form (Form A vs Form B) is produced, and
- the analytical fingerprints (XRPD peak sets, plus DSC for Form A).
Likely “competitive relevance” zones
Based on the claim set alone, infringement exposure is concentrated where a product is:
- marketed and manufactured as an anhydrous crystalline monophosphoric acid salt and matches Form A XRPD peaks (Claims 3–7 and 6), or
- manufactured as that anhydrous crystalline monophosphoric acid salt and matches Form B XRPD peaks (Claims 10–11), or
- marketed as a crystalline dihydrate hydrochloride with matching XRPD peaks (Claims 13–15).
Likely “weak points” to test in freedom-to-operate workflows
From a risk-management standpoint, the hardest-to-change parameters during scale-up are:
- hydration control (especially for Claim 13: crystalline dihydrate),
- XRPD peak positions (which can shift with particle size, instrumentation, and conditions, but claim language uses “about” values and multiple peaks),
- reproducibility of Form A vs Form B.
If a competitor can produce an alternative solid form whose XRPD peak set does not satisfy the “at least 3 peaks” threshold of Claim 6 (Form A) and does not satisfy any of the asserted peak presence for Claim 10 (Form B), it can reduce exposure. But the combination of “substantially as shown in FIG.” language can limit the margin for error.
What does claim scope suggest about enforcement focus and litigation posture?
The claim structure points to an enforcement narrative anchored in:
- comparative XRPD against the patent figures and enumerated peaks, and
- DSC comparisons for Form A claims 8–9.
This increases the probability that, in dispute, the case will turn on laboratory data under claim-defined conditions. The claims are built to accept partial matches (“one or more,” “at least 3,” figure-based substantiality) rather than requiring an exact full-pattern replication.
How do the dependent claims relate to each other (coverage layering)?
For the monophosphoric acid salt:
- Claim 1 (salt identity) is the broad base.
- Claim 2 narrows to anhydrous crystalline.
- Claims 3–9 carve Form A using XRPD and then DSC.
- Claims 10–11 carve Form B using XRPD and then figure comparison.
For the hydrochloride salt:
- Claim 12 is broad salt identity.
- Claim 13 narrows to crystalline dihydrate.
- Claim 14 and Claim 15 define the XRPD signature of that dihydrate.
This layering means infringement can be found at multiple levels depending on what the accused product actually is and how it is characterized.
What is the business takeaway for R&D and product teams?
1) Product classification is destiny. Labeling a candidate as “monophosphoric acid salt” or “hydrochloride salt” is necessary but not sufficient; the solid-state form and analytical fingerprint drive whether dependent claims read on the product.
2) XRPD peak strategy matters more than morphology. The claim set enumerates specific 2θ values and permits selection-based compliance, so avoiding even a subset of the peaks may still fail depending on how many peaks overlap the allowed sets.
3) For hydrochloride, dehydration is the key. The dihydrate requirement in Claim 13 is the major boundary condition.
4) For monophosphoric acid Form A, DSC helps but does not replace XRPD. Claims 3–7 and 6 can still read on products even if DSC onset differs, while Claims 8–9 add additional constraints only for Form A.
Key Takeaways
- US 9,067,896 is a salt and solid-form patent for a Formula I compound, with enforceability centered on monophosphoric acid salts (Form A and Form B) and a crystalline hydrochloride dihydrate.
- XRPD peak-based language dominates: Form A includes an XRPD peak at about 15° (Claim 3) and a “≥3 peaks” constraint within 13.7°, 15°, 16.8°, 21.3°, 22.4° (Claim 6); Form B is defined by enumerated peaks on an “one or more” basis (Claim 10).
- DSC provides an extra gate only for Form A via endotherm onset at about 184°C (Claim 8) and figure-based thermogram matching (Claim 9).
- Hydration state sharply narrows hydrochloride coverage to a crystalline dihydrate (Claim 13), then XRPD defines the fingerprint (Claims 14–15).
FAQs
1) Does the patent claim only the active compound?
No. It claims salts of the compound of Formula I, including a monophosphoric acid salt and a hydrochloride salt, with dependent claims restricting to specific solid forms and hydration states.
2) What differentiates Form A from Form B of the monophosphoric acid salt?
Form A is defined by XRPD peak requirements centered on ~15° and a set allowing at least 3 peaks among 13.7°, 15°, 16.8°, 21.3°, 22.4° (Claims 3 and 6), plus optional DSC features (Claims 8–9). Form B is defined by XRPD peaks selected from 9.3°, 12.5°, 13.4°, 15.8°, 17° (Claim 10).
3) Is DSC required to infringe the patent?
Not for all claims. DSC is required only for Form A claims 8–9. XRPD-based claims 3–7 and 6 do not require DSC.
4) What is the key hydration constraint for the hydrochloride salt?
Claim 13 requires the hydrochloride salt to be a crystalline dihydrate. That dihydrate condition is part of the dependent claim chain for the XRPD fingerprint claims.
5) How broad is the XRPD coverage in dependent claims?
It is broad enough to capture partial overlaps because several claims use “one or more” characteristic peaks and Claim 6 uses an “at least 3 peaks” logic. “Substantially as shown” figure language also expands interpretation beyond exact peak-by-peak matching.
References
[1] US Patent 9,067,896. Claims 1–15 (monophosphoric acid salt Form A and Form B; crystalline hydrochloride dihydrate; XRPD and DSC defining features).
